about
Regulating anxiety with extrasynaptic inhibition.Behavioral effects of the benzodiazepine-positive allosteric modulator SH-053-2'F-S-CH₃ in an immune-mediated neurodevelopmental disruption model.Selective targeting of the α5-subunit of GABAA receptors relaxes airway smooth muscle and inhibits cellular calcium handlingEster to amide substitution improves selectivity, efficacy and kinetic behavior of a benzodiazepine positive modulator of GABAA receptors containing the α5 subunit.First In Vivo Testing of Compounds Targeting Group 3 Medulloblastomas Using an Implantable Microdevice as a New Paradigm for Drug Development.Development of GABAA Receptor Subtype-Selective Imidazobenzodiazepines as Novel Asthma TreatmentsSex-Dependent Anti-Stress Effect of an α5 Subunit Containing GABAA Receptor Positive Allosteric Modulator.Prior antipsychotic drug treatment prevents response to novel antipsychotic agent in the methylazoxymethanol acetate model of schizophreniaSh-I-048A, an in vitro non-selective super-agonist at the benzodiazepine site of GABAA receptors: the approximated activation of receptor subtypes may explain behavioral effects.Phosphinophosphonates and Their Tris-pivaloyloxymethyl Prodrugs Reveal a Negatively Cooperative Butyrophilin Activation Mechanism.Further evaluation of the potential anxiolytic activity of imidazo[1,5-a][1,4]diazepin agents selective for α2/3-containing GABAA receptors.Pharmacological and antihyperalgesic properties of the novel α2/3 preferring GABAA receptor ligand MP-III-024.Synthesis and Characterization of a Novel γ-Aminobutyric Acid Type A (GABAA) Receptor Ligand That Combines Outstanding Metabolic Stability, Pharmacokinetics, and Anxiolytic EfficacyCharacterization of GABAA receptor ligands with automated patch-clamp using human neurons derived from pluripotent stem cellsAbuse-related effects of subtype-selective GABAA receptor positive allosteric modulators in an assay of intracranial self-stimulation in rats.eEF2K/eEF2 Pathway Controls the Excitation/Inhibition Balance and Susceptibility to Epileptic Seizures.Negative allosteric modulation of alpha 5-containing GABAA receptors engenders antidepressant-like effects and selectively prevents age-associated hyperactivity in tau-depositing mice.Optimization of substituted imidazobenzodiazepines as novel asthma treatments.Alleviation of Multiple Asthmatic Pathologic Features with Orally Available and Subtype Selective GABAA Receptor Modulators.Antinociceptive Effects of a Novel α2/α3-Subtype Selective GABAA Receptor Positive Allosteric Modulator.Mixed Aryl Phosphonate Prodrugs of a Butyrophilin Ligand.The butyrophilin 3A1 intracellular domain undergoes a conformational change involving the juxtamembrane region.Neonatal bladder inflammation induces long-term visceral pain and altered responses of spinal neurons in adult rats.Bioisosteres of ethyl 8-ethynyl-6-(pyridin-2-yl)-4 H -benzo[ f ]imidazo [1,5- a ][1,4]diazepine-3-carboxylate (HZ-166) as novel alpha 2,3 selective potentiators of GABA A receptors: Improved bioavailability enhances anticonvulsant efficacyCorrigendum: Regulating anxiety with extrasynaptic inhibitionAn antidepressant-related pharmacological signature for positive allosteric modulators of α2/3-containing GABAA receptors
P50
Q27312018-E0900B3B-842A-4EE0-BCB3-BF0681DE72C8Q30405706-B4B788CB-0547-4DB2-91FD-FCD1E5BB2A38Q30647960-044B2195-FE76-487F-A92D-7DD7424C3095Q34540561-10A6107A-93C2-450B-92F0-2B7598C2128FQ36056262-3BB1A788-806B-47F3-A10F-D3B9C82AB34CQ36984229-33A52D8E-E662-4C8B-AAF0-FB061F705226Q37428156-B7942E78-FE65-4A78-9126-9C2F8C2251DAQ37598278-E6A70573-BD9B-426B-9DD6-AA6A47CF5318Q37718608-CE49E3B3-7942-47EC-A596-F1A7D359CFF0Q38715641-187F8267-10F4-49F6-AFD2-E86FE9DC7BCBQ38820230-1CB604BF-C98F-4382-9F27-E77EB2907D56Q38924891-8A661018-89F7-43A7-87D4-927DDE4F1A1FQ40819756-0518D88B-B7F0-4E1A-B46E-36E8733FB1B3Q42756275-5D451EE0-3882-474B-84AE-44E1F26C7124Q45056140-698B6714-D77F-40A3-B435-D0143250D7B7Q47448046-6EEEAF3C-94AA-4F56-BC32-D36DFC7AF5F3Q47644867-04D86E5D-092D-4515-BCF7-A4CFD796BC57Q48027426-5732E673-A305-4E61-B819-B9E1D7EDBE96Q48235236-46DE5A00-11A5-4F11-ADA1-8C87D27CBB16Q48284984-A369377A-5EE2-41EA-A13B-874DB9B0D3EDQ49838268-C1930734-50FC-4EB4-9C75-22802B49832FQ50892187-B436EE72-ADEA-47E0-8B48-012445CC5C54Q51167310-DAFE21C1-AB15-416D-8F25-C4EDE20705FBQ60721484-2257BC01-A7CF-41E0-897B-F7B91ACDA481Q86802277-8CC76B5C-9823-496E-824E-A5A7524D07F6Q88532235-3E8ADEE6-48C6-4D12-8292-B268B444D83E
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Michael M Poe
@ast
Michael M Poe
@en
Michael M Poe
@es
Michael M Poe
@nl
type
label
Michael M Poe
@ast
Michael M Poe
@en
Michael M Poe
@es
Michael M Poe
@nl
prefLabel
Michael M Poe
@ast
Michael M Poe
@en
Michael M Poe
@es
Michael M Poe
@nl
P106
P1153
55621715600
P31
P496
0000-0002-8054-2947